Scarica l'app Stockscreener
2.345
2.70%
-0.065
Pre-mercato:
2.30
-0.045
-1.92%
Precedente Chiudi:
$2.41
Aprire:
$2.91
Volume 24 ore:
71.94M
Relative Volume:
19.72
Capitalizzazione di mercato:
$199.72M
Reddito:
-
Utile/perdita netta:
$-59.69M
Rapporto P/E:
-1.6871
EPS:
-1.39
Flusso di cassa netto:
$-46.54M
1 W Prestazione:
-11.84%
1M Prestazione:
+17.25%
6M Prestazione:
+42.12%
1 anno Prestazione:
+30.28%
Intervallo 1D:
$2.10
$2.92
Intervallo di 1 settimana:
$1.61
$3.06
Portata 52W:
$0.6254
$3.06
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
Nome
Milestone Pharmaceuticals Inc
Settore
Industria
Telefono
(514) 336-0444
Indirizzo
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Confronta MIST con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
2.345 | 205.26M | 0 | -59.69M | -46.54M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-11 | Iniziato | Wells Fargo | Overweight |
| 2025-06-05 | Ripresa | H.C. Wainwright | Buy |
| 2024-08-22 | Iniziato | Rodman & Renshaw | Buy |
| 2023-06-20 | Downgrade | Jefferies | Buy → Hold |
| 2022-04-22 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-03-05 | Iniziato | H.C. Wainwright | Buy |
| 2020-07-29 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-07-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-03-25 | Downgrade | Jefferies | Buy → Hold |
| 2020-03-24 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-03-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2019-06-04 | Iniziato | Oppenheimer | Outperform |
| 2019-06-03 | Iniziato | Cowen | Outperform |
| 2019-06-03 | Iniziato | Jefferies | Buy |
| 2019-06-03 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Milestone Pharmaceuticals Inc Borsa (MIST) Ultime notizie
Milestone Pharmaceuticals Poised for Success with Cardamyst Approval and Strong Market Potential - TipRanks
Milestone Pharmaceuticals: Cardamyst Beat Placebo, But The Commercial Bar Is Higher (MIST) - Seeking Alpha
Milestone Embarks On ‘Show-Me’ Story With Cardamyst Launch - Citeline News & Insights
Best Penny Stocks To Watch TodayDecember 15th - MarketBeat
Milestone Pharmaceuticals stock rating upgraded by TD Cowen to Buy on FDA approval - Investing.com Canada
MIST Stock Upgraded to 'Buy' by TD Cowen with New Price Target | - GuruFocus
MIST: Analyst Raises Price Target by 60% Amid Positive Outlook | - GuruFocus
Milestone Pharmaceuticals (NASDAQ:MIST) Raised to Buy at TD Cowen - MarketBeat
Milestone’s long regulatory road ends in approval for Cardamyst - PharmaLive
Milestone Pharmaceuticals Gains FDA Approval for CARDAMYST - TipRanks
Why Is Milestone Pharmaceuticals Stock Skyrocketing Monday?Milestone Pharmaceuticals (NASDAQ:MIST) - Benzinga
Milestone Pharmaceuticals (MIST) Stock: Wild Price Swings Follow FDA Approval Decision - Blockonomi
Milestone Pharmaceuticals shares rally after FDA greenlights first at-home PSVT nasal therapy - MSN
MIST Stock Soars Pre-Market After FDA Approves First Commercial Product – Retail Remains Bullish, Dismisses ‘Sell The News’ Concerns - Stocktwits
Milestone Pharma gains on FDA approval of nasal spray for patients with heart condition - TradingView — Track All Markets
Milestone wins first-ever FDA approval with green light for heart arrhythmia nasal spray - Fierce Pharma
Milestone Pharmaceuticals (MIST) Stock: FDA Approval of CARDAMYST, Launch Timeline, and Analyst Forecasts (Dec. 15, 2025) - ts2.tech
Milestone Pharmaceuticals (NASDAQ:MIST) Strengthens Cardiovascular Research - Kalkine Media
Milestone Pharmaceuticals (MIST) Receives FDA Approval for CARDA - GuruFocus
Milestone Pharmaceuticals Sees Stock Recovery Despite Market Volatility - StocksToTrade
MIST Stock Plummets Amid Financial Turmoil and Market Unrest - timothysykes.com
Milestone Pharmaceuticals (MIST) Stock This Week: FDA Approves CARDAMYST, Shares Whipsaw Into the Weekend — Week Ahead Outlook (Updated Dec. 13, 2025) - ts2.tech
Milestone Pharmaceuticals (NASDAQ:MIST) Downgraded by Wall Street Zen to Sell - MarketBeat
Milestone (NASDAQ: MIST) gains FDA approval for self-use CARDAMYST PSVT spray - Stock Titan
Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) - Yahoo Finance
Rocket Lab (RKLB) Stock News Today: Neutron “Hungry Hippo” Milestone, Launch Updates, and Analyst Forecasts (Dec. 12, 2025) - ts2.tech
Milestone Pharmaceuticals (MIST) Stock Update: FDA Approves CARDAMYST (Etripamil) — This Week’s Volatility, Analyst Forecasts, and What to Watch Next (Updated Dec. 12, 2025) - ts2.tech
Milestone Pharmaceuticals Eyes FDA Approval Amid Strong Q3 Results - timothysykes.com
A new trading data show Milestone Pharmaceuticals Inc (MIST) is showing positive returns. - setenews.com
Is Milestone Pharmaceuticals Inc. stock recession proofDip Buying & Long-Term Growth Stock Strategies - Newser
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Milestone Pharmaceuticals (Nasdaq: MIST) issues 30,000 options at $2.69 under 2021 Inducement Plan - Stock Titan
Stock Traders Purchase Large Volume of Call Options on Milestone Pharmaceuticals (NASDAQ:MIST) - MarketBeat
EV Market: Will Milestone Pharmaceuticals Inc. stock gain from lower inflationJuly 2025 Momentum & Advanced Swing Trade Entry Plans - BỘ NỘI VỤ
Milestone Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:MIST) - Defense World
Milestone Pharmaceuticals Inc (MIST) Performance and Fundamentals Dashboard tells a completely different story - Setenews
Will Milestone Pharmaceuticals Inc. stock gain from lower inflation2025 Volatility Report & AI Enhanced Trading Alerts - BỘ NỘI VỤ
Healthy Upside Potential: Milestone Pharmaceuticals Inc (MIST) - setenews.com
Jefferies Lifts Milestone Pharmaceuticals (MIST) Price Targets on Product Sales Prospects - Insider Monkey
Local Pharmaceutical Company Earns $200 Million Milestone Payment in Sarepta Partnership - Pasadena Now
Grasim Industries Limited Trading Near Value Zone Recovery AheadRetail Investor Activity & Low Entry Risk Stocks - earlytimes.in
13 Best Canadian Penny Stocks to Buy Right Now - Insider Monkey
Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics - Business Wire
Milestone Pharmaceuticals (NASDAQ:MIST) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Milestone Pharmaceuticals Prepares for CARDAMYST Launch Amid Financial Growth - MSN
Milestone Pharmaceuticals Inc. (MIST) stock price, news, quote and history - Yahoo Finance UK
Milestone Pharmaceuticals Inc. (MIST) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Is Milestone Pharmaceuticals Inc. stock bottoming outJuly 2025 Trade Ideas & Daily Stock Momentum Reports - newser.com
How analysts rate Milestone Pharmaceuticals Inc. stock today2025 Market Trends & Daily Oversold Bounce Ideas - newser.com
Published on: 2025-11-20 02:01:48 - newser.com
Can Milestone Pharmaceuticals Inc. recover in the next quarter2025 Market Sentiment & Free Reliable Trade Execution Plans - newser.com
Milestone Pharmaceuticals Inc Azioni (MIST) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):